Local oestrogen production, i.e. the conversion of C19 steroids to oestrogens catalysed by aromatase cytochrome P450, has been considered to play important roles in the progression of human oestrogen-dependent neoplasms (Sasano et al., 1994; Bulun et al., 1994) . We previously demonstrated the presence of possible in situ production of oestrogens in the stromal cells of endometrial carcinoma by immunohistochemistry, in situ hybridisation and biochemical methods (Watanabe et al., 1995) . Simpson et al. have demonstrated that the human aromatase gene contains a number of tissue-specific promoters that direct aromatase expression in human placenta as well as in human ovarian and adipose stromal cells (Means et al., 1989 Mahendroo et al., 1991) . In addition, tissue-specific expression of the human aromatase gene by alternative ulitisation of multiple exons 1 as novel promoters has been recently demonstrated to contribute to overexpression of aromatase in situ in various human sex steroid-dependent neoplasms (Harada et al., 1993; Bulun et al., 1994a, b) . Bulun et al. (1994c) , in particular, studied aromatase gene expression in eight cases of endometrial carcinoma and detected varying levels of P450arom transcripts in all eights cases. However, they examined alternative promoter use in only two cases and did not study the correlation of the promoters used and overexpression of aromatase genes. Therefore, in this study, we examined exons 1 of the human aromatase gene in seven cases of endometrioid endometrial carcinoma using the products of reverse transcription-polymerase chain reaction (RT-PCR) analysis to examine whether such an alternative splicing is present in this neoplasm. We also examined whether the use of any specific exons 1 may be correlated with aromatase expression in the specimens, which was determined by quantitation of aromatase mRNA in RT-PCR products and immunohistochemistry, in order to characterise further the in situ oestrogen metabolism of human endometrial malignancies.
Materials and methods Endometrial carcinoma
Seven endometrioid endometrial carcinoma specimens were collected at Tohoku University Hospital, Sendai, Japan, in 1994. The clinical and pathological findings are summarised in Table I . This histopathological classification was based on the World Health Organization Typing of Uterine Tumors (Silverberg and Kurman, 1992) . These specimens were immediately frozen and stored at -80°C until use. Specimens for immunohistochemical study were fixed in 4% paraformaldehyde (pH 7.4) for 18 h at 4°C and embedded in paraffin.
Immunohistochemistry
Immunohistochemical procedures employed in this study were described previously by Watanabe et al. (1995) . Immunostaining was carried out by the biotin-streptavidin amplified method using the Histofine immunostaining system (Nichirei, Tokyo, Japan).
The primary antibody used in this study was rabbit IgG anti-aromatase antibody prepared against enyzme purified from human placenta (Harada et al., 1988) . Preparation of the antibody and immunoblotting and immunohistochemical techniques using this antibody have been described elsewhere (Sasano et al., 1994; Harada, 1988) . Control sections were incubated with normal rabbit serum or 0.01 M phosphatebuffered saline solution (PBS). No immunoreactivity was observed in these control sections. The aromatase labelling index, or the number of stromal cells in which relatively strong aromatase immunoreactivity was observed, was defined as follows: (-) 0-5%; (+) 5-25% and (+ +) >25% positive cells among the stromal cells in the carcinoma, as previously described by Watanabe et al. (1995) .
Quantitative analysis of aromatase mRNA by RT-PCR The methods have been previously described by Harada et al. (1992a Harada et al. ( ,b, 1996 . Briefly, samples were homogenised in five volumes of 5 M guanidine thiocyanate containing 5 mM sodium citrate and 0.5% sodium sarcosyl. The total RNA fraction from all homogenates was prepared as described by Chingwin et al. (1979) . The measurement of aromatase mRNA in these samples was performed by RT -PCR using a specific sense primer labelled with a fluorescent dye and a specific antisense primer as previously described (Harada et al., 1992a, b) . The internal standard RNA used in the assays was synthesised in vitro from modified aromatase cDNA with 0.01 amol of human aromatase RNA containing a 21-base insertion as an internal standard and amplified by PCR for 26 cycles using a fluorescent dye (FAM) labelled primer. A FAM-labelled sense primer (5'-TACTACAACCGGGTA-TATGG-3', the sequence in exon 3) and an antisense primer (5'-TATTAGAGGTGTCCAGCATG-3', the sequence in exon 5) were used in the PCR for quantitative analysis of Figure la . The amount of aromatase mRNA in the tissue RNA was calculated from the peak areas of fluorescent products by the internal standard, as previously described (Harada et al., 1992a, b) . The amount of aromatase mRNA was calculated from the peak areas of two fluorescent peaks corresponding to aromatase mRNA and the modified aromatase mRNA (described above) as an internal standard.
Use of alternative exon I The use of alternative exons 1 of the aromatase gene was examined by RT-PCR of the RNA fraction using sense primers specific for exons la, lb, lc and Id and the fluorescent dye-labelled antisense primer specific for exon 2, as described previously (Harada et al., 1993 Means et al., 1991) , although the splice junction upstream of the translation start site in exon 2 is identical in every tissue and the expressed protein is, therefore, the same regardless of the splicing patterns. In human endometrium, P450arom expression has been detected in carcinoma but not in benign counterparts of this tissue (Watanabe et al., 1995; Bulun et al., 1993 Bulun et al., , 1994c 
